Prelude Therapeutics Reports Full Year 2022 Financial Results and Provides Corporate Update
Prelude Therapeutics Incorporated (PRLD)
Company Research
Source: GlobeNewswire
Four differentiated clinical compounds progressing through Phase 1 towards key data milestones Eight abstracts accepted for presentation at the 2023 American Association for Cancer Research (AACR) Annual Meeting Cash balance of $201.7 million as of December 31, 2022; runway remains unchanged through Q4 2024 WILMINGTON, Del., March 15, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today reported its financial results for the fiscal year ended December 31, 2022, and provided a corporate update. “We made considerable progress in 2022, including the filing and acceptance of two new INDs for our next generation CDK4/6 inhibitor and our first-in-class, highly selective SMARCA2 degrader. Our current clinical pipeline consists of four differentiated and internally discovered molecules that effectively target and block key oncogenic pathways in both hematological malignancies and solid tumors. Prelude
Show less
Read more
Impact Snapshot
Event Time:
PRLD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PRLD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PRLD alerts
High impacting Prelude Therapeutics Incorporated news events
Weekly update
A roundup of the hottest topics
PRLD
News
- Several Insiders Invested In Prelude Therapeutics Flagging Positive News [Yahoo! Finance]Yahoo! Finance
- Prelude Highlights Continued Strength of Discovery Engine at 2024 AACR Annual Meeting [Yahoo! Finance]Yahoo! Finance
- Prelude Highlights Continued Strength of Discovery Engine at 2024 AACR Annual MeetingGlobeNewswire
- Prelude Therapeutics Incorporated (NASDAQ: PRLD) is now covered by analysts at JMP Securities. They set an "outperform" rating and a $7.00 price target on the stock.MarketBeat
- Prelude Announces Acceptance of Multiple Preclinical Abstracts at the 2024 AACR Annual Meeting [Yahoo! Finance]Yahoo! Finance
PRLD
Earnings
- 8/3/23 - Beat
PRLD
Sec Filings
- 4/10/24 - Form 8-K
- 4/8/24 - Form 4
- 3/4/24 - Form 4
- PRLD's page on the SEC website